RSLS — ReShape Lifesciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for ReShape Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-12.3	-61.9	-46.2	-11.4	-7.13
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	2.48	47.4	21.9	2.26	0.339
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1.4	-2.74	0.709	-8.01	2.34
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-10.4	-15.4	-21.9	-17	-4.43
Capital Expenditures	-0.171	-0.352	-0.131	-0.043	0
Purchase of Fixed Assets
Other Investing Cash Flow Items	0	2.21	0.039	0.033	0
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Cash from Investing Activities	-0.171	1.85	-0.092	-0.01	0
Financing Cash Flow Items	—	-3.23	0	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	0.43	33.3	3.13	17.6	0.677
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-10.2	19.8	-18.9	0.604	-3.77